GDC-0879 is a highly selective, novel potent, orally bioavailable B-Raf inhibitor in various in vitro and cell-based assays with an IC50 estimate of 0.13 nM against purified B-Raf V600E enzyme and a cellular pERK IC50 of 63 nM in the MALME-3M cell line.For this compound, subnanomolar enzyme potency translated into very effective reduction of cellular viability of BRAF-mutant Malme3M cells (EC50 values were 0.75 umol/L for GDC-0879).In GDC-0879-treated mice, both cell line- and patient-derived BRAFV600E tumors exhibited stronger and more sustained pharmacodynamic inhibition (>90% for 8 hours) and improved survival compared with mutant KRAS-expressing tumors.   ^[1]

 

 

[1] Cancer Res. 2009, 69, 3042-3051.

Molecular Weight (WM):	334.37
Formula:	C19H18N4O2
CAS No:	905281-76-7
Purity:	≥ 98%
Synonyms:	GDC0879, GDC-0879
	DMSO ≥ 67 mg/mL
Solubility: (R.T.: 25℃):	Water < 1 mg/mL
	Ethanol ≥ 5 mg/mL
	2 years     -20℃        Powder
Stability:	2 weeks     -4℃        in DMSO
	2 months    -80℃       in DMSO

Quality control data:

Quality control by 1H-NMR, 13C-NMR, HPLC and LCMS.

Product will be shipped with supporting analytical data.